Live Analyst Rating Changes 26278 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Keay Nakae
CHAR

Keay Nakae

Chardan Capital
Wall Street Analyst
★★☆☆☆
#2527
on 13Foresight · ranked by our own returns
51%
Success Rate
+11.5%
Average Return
33 of 65 calls profitable · +32.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 51% of Keay Nakae's ratings turned a profit when each position was held for 1 year — averaging +11.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

58 Buy 4 Hold 0 Sell
Keay's Stock Coverage 69 ratings · 2026-08-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
SLN
Silence Therapeutics
 Aug 16, 2026 BUY Buy
+154.5% avg upside
10 analysts
 — · ·
PMN
ProMIS Neurosciences
 Aug 13, 2026 BUY Strong Buy
+342.3% avg upside
9 analysts
$33.00
120.29% Upside
 +0.5% ·
MGX
Metagenomi, Inc.
 Aug 10, 2026 BUY Strong Buy
+587.2% avg upside
8 analysts
$5.00
313.16% Upside
 +0.0% ·
ES:PHM
Pharma Mar SA
 Aug 09, 2026 BUY Strong Buy
+33.1% avg upside
4 analysts
$100.00
23.05% Upside
 +4.5% ·
KRRO
Korro Bio
 Aug 06, 2026 BUY Strong Buy
+95.8% avg upside
19 analysts
$15.00
13.50% Upside
 +15.1% ·
ARWR
Arrowhead Pharmaceuticals
 Aug 04, 2026 BUY Buy
-15.4% avg upside
27 analysts
$115.00
30.79% Upside
 -3.3% ·
STOK
Stoke Therapeutics
 Aug 03, 2026 BUY Strong Buy
+21.8% avg upside
18 analysts
$35.00
8.85% Upside
 +5.8% ·
DYN
Dyne Therapeutics
 Jul 29, 2026 BUY Strong Buy
+49.8% avg upside
31 analysts
$38.00
46.18% Upside
 +4.2% ·
FR:ALSEN
Sensorion SAS
 Jul 19, 2026 BUY Strong Buy
+423.6% avg upside
6 analysts
$1.00
244.18% Upside
 +16.8% ·
FR:SIGHT
GenSight Biologics SA
 Jul 15, 2026 HOLD Buy
+6948.9% avg upside
3 analysts
$0.08
20.93% Downside
 +20.8% ·
IBIO
Ibio
 Jul 01, 2026 BUY Strong Buy
+292.7% avg upside
11 analysts
$5.00
244.93% Upside
 -18.3% ·
PRQR
ProQR
 Jun 25, 2026 BUY Strong Buy
+412.6% avg upside
19 analysts
$3.00
39.62% Upside
 +22.3% ·
SABS
SAB Biotherapeutics
 Jun 16, 2026 BUY Strong Buy
+181.9% avg upside
14 analysts
$16.00
322.08% Upside
 +3.3% ·
CAMP
CAMP4 Therapeutics Corporation
 Jun 10, 2026 BUY Strong Buy
+111.6% avg upside
9 analysts
$6.50
32.69% Upside
 +25.4% ·
COYA
Coya Therapeutics, Inc.
 May 12, 2026 BUY Strong Buy
+222.3% avg upside
7 analysts
$14.00
184.62% Upside
 +11.7% ·
ALNY
Alnylam Pharma
 May 01, 2026 BUY Strong Buy
+34.8% avg upside
51 analysts
$425.00
85.92% Upside
 -22.6% ·
ANRO
Alto Neuroscience, Inc.
 Apr 21, 2026 BUY Strong Buy
-7.6% avg upside
13 analysts
$30.00
12.16% Downside
 +36.3% ·
JP:4593
Healios KK
 Apr 07, 2026 BUY Strong Buy
+179.4% avg upside
3 analysts
$800.00
208.78% Upside
 -28.8% ·
OBIO
Orchestra BioMed Holdings
 Mar 12, 2026 BUY Strong Buy
+140.2% avg upside
9 analysts
$20.00
253.31% Upside
 +0.7% ·
ALURD
Allurion Technologies
 Feb 24, 2026 BUY Strong Buy
+3459.8% avg upside
4 analysts
$45.00
1530.50% Upside
 +155.0% ·
RVPH
Reviva Pharmaceuticals Holdings
 Jan 05, 2026 BUY Strong Buy
+8985.5% avg upside
9 analysts
$40.00
8595.70% Upside
 -92.3% ·
FR:AB
AB Science SA
 Sep 30, 2025 BUY Buy
+615.3% avg upside
2 analysts
$5.00
615.31% Upside
 -43.3% ·
MNPR
Monopar Therapeutics Inc
 Sep 25, 2025 BUY Strong Buy
-15.2% avg upside
18 analysts
$85.00
28.66% Downside
 +53.7% ·
MCRB
Seres Therapeutics
 May 08, 2025 HOLD Buy
+257.7% avg upside
11 analysts
$6.00
38.23% Upside
 +10.7% ·
MARA
MARA Holdings
 Dec 20, 2024 HOLD Strong Buy
+98.9% avg upside
23 analysts
 — -49.0% ·
GWH
ESS Tech
 Dec 20, 2024 HOLD Buy
+631.2% avg upside
11 analysts
$12.00
1709.48% Upside
 -57.3% ·
PPBT
Purple Biotech
 Dec 20, 2024 HOLD Strong Buy
+2038.4% avg upside
4 analysts
 — -79.3% ·
SYBX
Synlogic
 Dec 20, 2024 HOLD Buy
+1865.7% avg upside
11 analysts
 — -15.5% ·
NTBLQ
Notable Labs
 Dec 20, 2024 HOLD Buy
+809999900.0% avg upside
12 analysts
 — · ·
ABUS
Arbutus Biopharma
 Nov 19, 2024 BUY Strong Buy
+79.0% avg upside
15 analysts
$5.00
3.21% Upside
 +22.4% ·
GANX
Gain Therapeutics
 Nov 18, 2024 BUY Strong Buy
+282.9% avg upside
9 analysts
$6.00
195.62% Upside
 +68.6% ·
FEMY
Femasys
 Nov 12, 2024 BUY Strong Buy
+2262.5% avg upside
6 analysts
$8.00
263.73% Upside
 · ·
BTTX
Better Therapeutics
 Mar 14, 2024 HOLD Strong Buy
+1499900.1% avg upside
3 analysts
 — · ·
MESO
Mesoblast
 Dec 12, 2023 HOLD Strong Buy
+44.6% avg upside
14 analysts
 — +399.0% ·
QTTB
Q32 Bio
 Mar 09, 2023 BUY Buy
+278.0% avg upside
24 analysts
 — -33.6% ·
PHGE
BiomX
 Feb 17, 2023 HOLD Hold
+18188.1% avg upside
4 analysts
 — · ·
FBRX
Forte Biosciences
 Feb 17, 2023 HOLD Buy
-35.4% avg upside
15 analysts
 — -30.9% ·
NVAX
Novavax
 Feb 17, 2023 HOLD Buy
+180.5% avg upside
20 analysts
 — -58.5% ·
EBS
Emergent Biosolutions
 Feb 17, 2023 HOLD Buy
+419.8% avg upside
9 analysts
 — -90.4% ·
IMTX
Immatics
 Feb 06, 2023 BUY Strong Buy
+99.3% avg upside
15 analysts
 — +31.9% ·
EVLO
Evelo Biosciences
 Nov 16, 2022 HOLD Hold
+4499999899.9% avg upside
5 analysts
$50.00
4999999899.95% Upside
 · ·
XCUR
Exicure
 Sep 30, 2022 HOLD Strong Buy
+6419.3% avg upside
4 analysts
 — -54.1% ·
KLDO
Kaleido Biosciences
 Apr 10, 2022 HOLD Buy
+13249900.0% avg upside
5 analysts
 — · ·
LCTX
Lineage Therap
 Jul 30, 2021 HOLD Strong Buy
+404.9% avg upside
16 analysts
 — -37.6% ·
ADMA
ADMA Biologics
 Jul 30, 2021 HOLD Strong Buy
+9.3% avg upside
15 analysts
 — +38.1% ·
CFRXQ
ContraFect
 Jul 30, 2021 HOLD Buy
+109699900.0% avg upside
10 analysts
 — · ·
ARCT
Arcturus Therapeutics
 Jul 30, 2021 HOLD Buy
+194.0% avg upside
36 analysts
 — -44.0% ·
IL:KMDA
Kamada
 Jul 30, 2021 HOLD Strong Buy
+63.8% avg upside
7 analysts
 — -8.0% ·
LSTA
Lisata Therapeutics
 Jul 30, 2021 HOLD Buy
+1056.2% avg upside
11 analysts
 — -62.4% ·
OCGN
Ocugen
 Jun 10, 2021 HOLD Strong Buy
+538.2% avg upside
17 analysts
$4.50
235.83% Upside
 -67.6% ·
STEX
Streamex
 Nov 20, 2020 HOLD Strong Buy
+974.1% avg upside
5 analysts
 — · ·
IMDX
Insight Molecular Diagnostics
 Jul 30, 2020 HOLD Buy
+23.1% avg upside
10 analysts
$2.00
53.36% Downside
 +252.1% ·
MRNA
Moderna
 Mar 23, 2020 BUY Hold
-42.6% avg upside
38 analysts
 — +413.8% ·
BIOCQ
Biocept
 Jan 28, 2020 HOLD Strong Buy
+84074899.9% avg upside
7 analysts
 — · ·
VRDN
Viridian Therapeutics
 Jun 10, 2019 HOLD Strong Buy
+43.4% avg upside
32 analysts
 — -57.6% ·
AKTX
Akari Therapeutics
 Jun 10, 2019 HOLD Strong Buy
+1114.2% avg upside
7 analysts
 — · ·
AIXC
AIxCrypto Holdings
 Feb 16, 2017 BUY Strong Buy
+646.5% avg upside
7 analysts
$4.50
240.95% Upside
 · ·
KPRX
Kiora Pharmaceuticals
 Dec 06, 2016 BUY Strong Buy
+244.4% avg upside
6 analysts
$6.00
131.57% Upside
 · ·
MBAI
Check-Cap
 Aug 23, 2016 BUY Strong Buy
+0.3% avg upside
5 analysts
$4.00
52.11% Downside
 · ·
CCLD
CareCloud
 Aug 12, 2016 BUY Strong Buy
+216.6% avg upside
9 analysts
$2.25
13.17% Downside
 +45.6% ·
ADYX
Adynxx
 Jul 08, 2016 BUY Strong Buy
+3387400.0% avg upside
4 analysts
$2.00
1999899.92% Upside
 · ·
MBOT
Microbot Medical
 Mar 28, 2016 BUY Strong Buy
+336.4% avg upside
7 analysts
$6.00
308.14% Upside
 · ·
ALDX
Aldeyra Therapeutics
 Dec 03, 2014 BUY Strong Buy
+914.3% avg upside
21 analysts
$16.00
932.24% Upside
 -4.6% ·
CNSY
Cerenome
 Aug 06, 2014 HOLD Strong Buy
+909.5% avg upside
11 analysts
$4.00
29.96% Upside
 · ·
GADS
Gadsden Prop
 May 15, 2014 HOLD Buy
+3599900.0% avg upside
5 analysts
$18.00
3599899.97% Upside
 · ·
GALT
Galectin Therapeutics
 Oct 07, 2013 BUY Strong Buy
+169.4% avg upside
8 analysts
$13.00
269.29% Upside
 -60.9% ·
BIOLQ
BIOLASE
 Jul 03, 2013 BUY Strong Buy
+1197999900.0% avg upside
6 analysts
$5.50
549999900.00% Upside
 · ·
TOVX
Theriva Biologics
 Jun 25, 2013 BUY Strong Buy
+3456.4% avg upside
8 analysts
$2.30
919.94% Upside
 · ·
VCEL
Vericel
 May 16, 2012 BUY Strong Buy
+8.6% avg upside
16 analysts
 — -73.8% ·
🔒 64 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Keay Nakae — Frequently Asked Questions
How accurate are Keay Nakae's stock ratings?
Based on the calls 13Foresight could measure, about 51% of Keay's ratings were profitable over a one-year hold, with an average return of +11.5% per rating, or +32.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Keay ranked on 13Foresight?
Keay Nakae is currently ranked #2527 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Keay cover?
Keay most recently has ratings on SLN, PMN, MGX, ES:PHM, KRRO, ARWR, STOK, DYN, FR:ALSEN, FR:SIGHT, IBIO, PRQR and 57 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.